Import Biomarker Diseases Diagnosis Blood Tests — Buy in wholesale FOB from Supplier in South Korea (Republic Of Korea)

The Biomarker Diseases Diagnosis Blood Tests from Bertis Inc. utilise a proteomic biomarker reagent formulated as a multi-analyte immunological composition. Designed for clinical laboratory and hospital deployment, the kit enables rapid early-stage detection of major diseases through quantitative measurement of disease-specific proteins in blood samples. The technology requires only trace volumes, a few drops of blood, to perform analysis, making it suitable for universal primary screening protocols. The product is available in bulk packaging for B2B distribution and requires cold chain storage throughout the supply chain.

The reagent system employs multi-biomarker immunoassay technology, combining antibodies against multiple protein targets to achieve high sensitivity and specificity in disease detection. Proteomics-based diagnosis identifies proteins specifically expressed in disease states and quantifies their concentrations in patient blood samples. The immunological composition is manufactured to IVD regulatory standards for international export, though buyers should confirm the exact regulatory classification (CE-IVD, FDA 510(k), or KFDA approval) applicable to their destination market. Cold chain integrity, typically maintained at 2-8°C, is critical to preserving reagent stability and assay performance.

Target buyers include clinical diagnostic laboratories, hospital central laboratories, reference laboratories, and IVD distributors serving healthcare systems. The assay format supports high-throughput workflows in early screening programmes for oncology, cardiovascular disease, and metabolic disorders. Buyers should confirm minimum order quantities, shelf life upon delivery, and the supplier's capacity for lot-to-lot consistency documentation. Incoterms, lead times, and freight arrangements for temperature-controlled shipment from Gyeonggi-Do to the buyer's port require direct negotiation with Bertis Inc.

Bertis Inc. is headquartered at 3rd Floor, B Building, 33 Gwacheon-daero 7-gil, Gwacheon-Si, Gyeonggi-Do, 13840, South Korea. The company holds a harbor trust tier on the platform, indicating a verified business registration with foundational credibility signals. The response rate is recorded at 0.00 percent with zero average response hours, which suggests either a new listing or limited historical transaction data through this channel. Buyers should initiate direct contact to assess responsiveness and technical support capabilities.

The supplier's profile focuses exclusively on proteomics-based diagnostic technology, with particular emphasis on multi-biomarker blood tests for early disease detection. No information is provided about manufacturing facility scale, ISO 13485 certification status, headcount, annual revenue, or named client institutions. The company does not state years in operation, previous export markets, or distribution partnerships. Buyers are advised to request documentation of quality management system certification, clinical validation data, and reference installations before committing to supply agreements.